What ProMIS Neurosciences does

ProMIS Neurosciences is a clinical-stage biotechnology company developing selective antibody therapeutics and vaccines for neurodegenerative diseases caused by misfolded proteins. Its core technology is the proprietary EpiSelect™ platform, a computational discovery engine combining protein biology, physics, and supercomputing to predict and identify Disease Specific Epitopes (DSEs) on toxic misfolded proteins, enabling generation of antibodies that selectively bind pathogenic isoforms while sparing normal ones. The pipeline is anchored by PMN310, a humanized IgG1 monoclonal antibody selectively targeting toxic amyloid-beta oligomers for early Alzheimer's disease, currently in the PRECISE-AD Phase 1b trial; complemented by PMN267 for ALS/TDP-43 proteinopathies and PMN442 for Parkinson's disease and synucleinopathies in preclinical stages, plus vaccine candidates PMN311 and PMN440.

The company is headquartered in Toronto, Ontario, with a U.S. office in Cambridge, Massachusetts, is publicly listed on Nasdaq under ticker PMN, and has a small team (1–10 employees) supplemented by Scientific and Clinical Advisory Boards. ProMIS is pre-revenue and does not currently sell commercial products; its business model contemplates future revenue from approved therapeutic sales through pharmaceutical distribution channels, with no pricing publicly disclosed at this stage. Capital formation is the dominant near-term revenue-side activity: the company has raised over $130 million in disclosed equity financings since 2023, including a January 2026 PIPE of up to $175 million co-led by Janus Henderson and Ally Bridge Group, with proceeds funding the PRECISE-AD Phase 1b trial, subcutaneous formulation development, and runway extension into 2028.

Commercially, ProMIS operates an investor- and partner-facing go-to-market motion typical of small-cap public biotechs, including conference participation (Jefferies, Wolfe, Oppenheimer, BIO, Bloom Burton), SEC and press-release communications, and institutional investor relations; clinical development and future commercialization are intended to be executed through traditional pharmaceutical distribution upon regulatory approval. Key value-creation catalysts in the near term are PMN310 Phase 1b readouts, advancement of PMN267 and PMN442 toward IND, and continued pipeline expansion leveraging the EpiSelect™ platform across additional misfolded protein targets.

Name

ProMIS Neurosciences

Legal name

ProMIS Neurosciences Inc.

Website

https://promisneurosciences.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

ProMIS Neurosciences is a clinical-stage biotech developing selective antibody therapeutics and vaccines for neurodegenerative diseases, using its proprietary EpiSelect™ platform to target toxic misfolded proteins in Alzheimer's, ALS, and Parkinson's patients.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals - Neurodegenerative Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Antibody therapeutics
• Neurodegenerative disease treatment
• Misfolded protein targeting
• Monoclonal antibody development
• Alzheimer's disease therapy

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Therapeutic Product Sales: ProMIS Neurosciences is a pre-revenue clinical-stage biotechnology company. The company does not currently generate any product revenue. Future revenue is expected to come from the sale of approved therapeutic products, once product candidates receive regulatory approval for commercial sale.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ProMIS Neurosciences is a clinical-stage biotechnology company that discovers and develops selective antibody therapeutics and vaccines targeting toxic misfolded proteins implicated in neurodegenerative diseases, including Alzheimer's disease (PMN310), ALS and TDP-43 proteinopathies (PMN267), and Parkinson's disease and synucleinopathies (PMN442), as well as AD and synucleinopathy vaccine candidates (PMN311, PMN440). Its proprietary EpiSelect™ platform computationally predicts and identifies Disease Specific Epitopes (DSEs) on misfolded proteins, enabling the generation of antibodies selective for pathogenic protein isoforms while sparing normal isoforms.

Product overview

ProMIS Neurosciences is a clinical-stage biotechnology company developing a portfolio of selective antibody therapeutics and vaccines for neurodegenerative diseases. The company's core platform is EpiSelect™, which enables the discovery of disease-specific epitopes on misfolded proteins. The lead product is PMN310, a monoclonal antibody for Alzheimer's disease currently in Phase 1b clinical trials. The pipeline includes PMN267 for ALS and PMN442 for Parkinson's disease/synucleinopathies, both in preclinical/IND-enabling stages. The company is also developing vaccine candidates (PMN311 for AD, PMN440 for synucleinopathies) leveraging the same epitope discovery platform.

Differentiator

Problem solved

Functional benefit

Products and services

• PMN310 - Amyloid-Beta Oligomer Antibody Humanized IgG1 monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβO) while avoiding plaque binding, intended as a treatment for Alzheimer's disease (including patients with Mild Cognitive Impairment due to AD and mild AD, Stage 3 and Stage 4). Currently in Phase 1b (PRECISE-AD) clinical trials with FDA Fast Track designation.
• PMN267 - TDP-43 Targeting Antibody

Quantifiable outcome

• Phase 1a trial demonstrated good safety and blood-brain barrier crossing with no treatment-related serious adverse events
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Two partnerships are on record, tiered strategic and core.

• MindWalk Holdings Corp.strategicStrategic or Co-development Partner · 18 May 2026MindWalk Holdings' antibody discovery work produced drug candidates for ProMIS Neurosciences as one of their partner companies. MindWalk's platform enables partner companies to advance clinical-stage programs originated through their discovery work. ProMIS Neurosciences is listed among MindWalk's partner companies including Annexon Biosciences, argenx, Xencor, and others.
• University of British Columbia (UBC)coreStrategic or Co-development Partner · 1 April 2016Collaborative research agreement with UBC and Vancouver Coastal Health Authority for research on misfolded proteins. Dr. Neil Cashman serves as principal investigator. The agreement was amended multiple times through February 2026, extending through February 2027 with aggregate funding increased to C$5,830,000.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Alector: Alector develops immuno-neurology antibodies for neurodegenerative diseases, including programs targeting TREM2 and other misfolded proteins. Comparable clinical-stage biotech with antibody pipeline addressing AD and FTD, partnered with GSK.
• Annovis Bio: Annovis Bio develops buntanetap for Alzheimer's and Parkinson's diseases, targeting multiple neurodegenerative indications in clinical stages. Small-cap clinical-stage biotech with similar focus on AD and PD therapeutics.
• Biogen: Biogen co-developed and commercializes lecanemab (Leqembi) with Eisai, the leading approved anti-amyloid antibody for Alzheimer's disease. Direct competitor to ProMIS's PMN310 in targeting amyloid pathology.
• AC Immune: AC Immune develops vaccines and antibodies targeting amyloid-beta, Tau, and alpha-synuclein for neurodegenerative diseases, including ACI-35.030 (anti-Tau vaccine). Highly comparable to ProMIS's platform approach spanning multiple misfolded protein targets with both antibody and vaccine modalities.
• Annexon Biosciences: Annexon develops classical complement pathway inhibitors for neurodegenerative diseases, with programs in Guillain-Barré syndrome, ALS, and geographic atrophy. Listed among MindWalk Holdings' partner companies alongside ProMIS, indicating comparable antibody discovery and development approach.
• Eisai: Eisai leads the development and commercialization of lecanemab (Leqembi) with Biogen. Direct competitor in anti-amyloid antibody therapeutics for Alzheimer's disease where ProMIS's PMN310 is also advancing.
• Denali Therapeutics: Denali Therapeutics develops therapeutics for neurodegenerative diseases, including antibody programs for Parkinson's and ALS. Clinical-stage biotech with similar neurodegenerative focus and partnered programs with major pharma (Biogen, Sanofi).
• Cassava Sciences: Cassava Sciences is developing simufilam for Alzheimer's disease. Clinical-stage biotech focused on AD therapeutics with a small-cap profile similar to ProMIS, competing for investor attention in the AD space.

Broad incumbents

• Eli Lilly: Eli Lilly developed donanemab (Kisunla), an approved anti-amyloid antibody for Alzheimer's disease. As a large incumbent with deep neurology infrastructure, Lilly represents both a direct competitive threat and a potential strategic acquirer of neurodegenerative pipelines like ProMIS's.

Emerging players

• Athira Pharma: Athira Pharma is developing small-molecule therapies for neurodegenerative diseases, with fosgonimeton in clinical development for Alzheimer's. Emerging player in neurodegenerative space with different modality but overlapping indication focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ProMISinc
• Facebookfacebook.com/promisneuro
• LinkedInlinkedin.com/company/promis-neurosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds21 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProMIS Neurosciences